Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces MAR001 Reduces Triglycerides Without Worsening Glycemic Control in Phase 2b TYDAL-TIMI 78 Trial; Results Presented as AHA 2026 Late-Breaker and Published in The New England Journal of Medicine
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November Investor Conferences
INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger - LFCR, LSTA, FSHP and BWIN - IS IT A FAIR DEAL FOR YOU?
Lisata adds biopharma finance veteran Jeffrey Farrow to board
Financial Survey: Lisata Therapeutics (NASDAQ:LSTA) vs. Dyadic International (NASDAQ:DYAI)
Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
Head to Head Analysis: GeoVax Labs (NASDAQ:GOVX) vs. Lisata Therapeutics (NASDAQ:LSTA)
Lisata Therapeutics wins new US patent for pancreatic cancer drug
Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors
Lisata subsidiary Marea treats first patient in MAR002 acromegaly trial
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
EQUITY ALERT - The M&A Class Action Firm Launches Inquiry -- LSTA, FSHP, BWIN, and ACVA
Lisata subsidiary Marea Therapeutics gets late-breaking slot at AHA Scientific Sessions
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026
Nano Cap Lisata Therapeutics Bolsters Cardioendocrine Pipeline Strategy
Lisata Therapeutics acquires Marea Therapeutics, secures $225 million private placement
Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement
Anthropic is compounding, OpenAI is flatlining, and the betting markets have noticed
Lisata Therapeutics moves forward with legal action following Kuva merger termination
Lisata Therapeutics Provides Update Following Termination of Merger Agreement